Moderna Highlights Near-Term Non-COVID Readouts As Pandemic Vaccine Sales Drop

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

The company attributed lower-than-expected vaccine sales to supply issues, but it expects some significant read-outs over the next few months in respiratory infections and oncology.

Moderna announced its third quarter 2022 earnings on 3 November • Source: Shutterstock

Moderna, Inc.’s sales for the third quarter fell short of analyst expectations, due to supply issues around its COVID-19 vaccines, and the company is anticipating that demand for those will soon begin to wind down. But it highlighted progress on its non-pandemic respiratory vaccine as well as other development programs, including its Merck & Co., Inc.-partnered cancer vaccine candidate.

The Cambridge, MA-based biotech announced its earnings on 3 November, reporting total revenues of $3.4bn for the quarter, down from...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.